Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > CD8+ TiLs and T-cell exhaustion

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Aug 10, 2024 2:48pm

71 Views

Post# 36172922

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:CD8+ TiLs and T-cell exhaustion

December 2023 - Poster at SABCS

T Cell Receptor Sequencing to Monitor Pelareorep-Induced Expansion of Tumor Infiltrating Lymphocytes (TiLs)

Conclusions

• These results confirm the previously reported CelTIL results from AWARE-1 demonstrating pelainduced increases in TILs post-treatment
• Clonal expansion of TILs was also observed in the blood
• Newly detected TIL clones were more prominent in the tumor • Pre-existing TIL clones were more prominent in the blood

https://oncolyticsbiotech.com/wp-content/uploads/2023/12/SABC-2023-AWARE-TIL-Expansion_Final_TH.pdf

<< Previous

Bullboard Posts

Next >>

E3 inches closer to Alberta's first lithium production plant